Prior Authorization Requirements for Specialty Medications: What's Changing in April 2026

If you've spent any time managing prior authorizations for specialty medications, you already know the drill — just when you think you've got a payer's requirements figured out, something shifts. April 2026 is shaping up to be one of those moments. Several major payers are updating their PA criteria for high-cost specialty drugs, and the practices that get ahead of these changes now will spend a lot less time fighting denials in May. Let's walk through what's actually changing, what it means for your workflows, and how to keep your patients' medications from getting interrupted.

What's Actually Changing This April

The headline changes center around a handful of drug categories that have been on payers' radar for cost management: biologics for inflammatory conditions (think rheumatoid arthritis, psoriasis, Crohn's disease), specialty oncology supportive care agents, and newer GLP-1 receptor agonists that are increasingly being prescribed for conditions beyond Type 2 diabetes.

Here's what the updates look like in practice:

• Step therapy requirements are getting stricter. Several commercial payers are now requiring documented failure of two conventional therapies before approving biologics, up from one in many cases. If you've been submitting with one prior therapy documented, your approval rates are about to take a hit.


• Genetic testing documentation is now required for some targeted therapies. This one catches practices off guard — you can't just submit a diagnosis code anymore. Some oncology agents now require biomarker testing results as part of the initial PA submission.


• GLP-1s for obesity indications are facing new BMI threshold requirements and comorbidity documentation. Several payers are tightening these criteria in response to the volume of requests they've been fielding.


• Reauthorization windows are shortening. Watch for plans moving from annual to 6-month reauth cycles for certain specialty drugs. This doubles your administrative burden for those patients without adding clinical value — frustrating, but it's the reality.

Medicare Advantage plans, in particular, seem to be leading this tightening trend. If a significant portion of your specialty patients are on MA plans, this needs to be a priority conversation with your billing and clinical teams.

The Documentation Mistakes That Are Costing You Approvals

Here's something I see constantly: practices submit complete clinical information, and they still get denied — not because the patient doesn't qualify, but because the documentation doesn't speak the payer's language. There's a difference between documenting that a patient "tried methotrexate without adequate response" and documenting that a patient "completed a 12-week trial of methotrexate at therapeutic doses with persistent disease activity as measured by [specific scale], documented on [dates]."

The second version is what payers want. The first version gets you a denial letter that says "insufficient documentation of step therapy failure."

A few specific documentation tips that actually move the needle:

Use the payer's own clinical criteria language. Most payers publish their coverage policies online. Pull the actual PA criteria document for the drug you're requesting and mirror that language in your submission. If their policy says "moderate-to-severe disease as defined by a score of X or higher on [assessment tool]," include that score and that assessment tool. Don't make reviewers hunt for it.

Date everything. Every trial, every lab result, every office visit where the patient reported inadequate control — dates matter. A PA reviewer can't approve step therapy failure they can't verify happened in a reasonable timeframe.

Include the "why now." If a patient has been on a medication for a year and you're reauthorizing, explain disease stability or why continued therapy is medically necessary. Don't assume the reviewer will connect those dots.

Building a Specialty PA Workflow That Doesn't Fall Apart

The practices that handle specialty PA volume well have one thing in common: they treat it as a dedicated workflow, not something that gets squeezed between other tasks. That sounds obvious, but most practices are still handling specialty PA reactively — a prescription gets written, someone submits a PA request, and then everyone crosses their fingers.

A proactive approach looks different. Before a specialty medication is even prescribed, your team should be running an eligibility and benefit check to understand what that payer's requirements are going to be. Some specialty drugs have peer-to-peer requirements built into the criteria — your physician needs to know that upfront, not after the first denial.

Consider building a specialty PA checklist by drug class that gets updated quarterly. This doesn't need to be elaborate — even a simple shared document that lists the top 15 specialty drugs you prescribe, with the current payer-specific requirements, saves enormous time. Assign someone ownership of keeping it current. When you get a denial that reveals a changed requirement, update the checklist that day.

For practices seeing high specialty drug volume, it's also worth knowing that AI-powered tools now exist that can help draft appeal letters and flag missing documentation elements before submission — not a replacement for clinical expertise, but genuinely useful for reducing the back-and-forth on first-level appeals.

When to Push Back: Denials That Shouldn't Stick

Not every denial deserves an appeal, but some absolutely do — and knowing the difference saves you from wasting time on appeals you'll lose while making sure you fight the ones you should win.

Appeals worth pursuing:

• Denials where the patient clearly meets criteria and documentation supports it. Sometimes things get denied because a reviewer missed something or the submission was incomplete. These are often overturned quickly with a targeted appeal.


• Denials citing "not medically necessary" when clinical guidelines support the treatment. If NCCN guidelines, ACR recommendations, or other major clinical society guidelines back the prescribed therapy, say so explicitly and cite the specific guideline and publication date.


• Denials based on a step therapy requirement your patient already completed elsewhere. If a patient transferred to your practice and has prior treatment history with another provider, get those records and include them. You shouldn't have to re-fail a therapy that already failed.

Peer-to-peer requests from the prescribing physician remain one of the most effective tools in the appeal arsenal. The overturn rate on peer-to-peers is meaningfully higher than written appeals alone — if your physicians are willing and the denial is worth fighting, get that call scheduled quickly. Most payers have short windows.

Keeping Patients on Therapy During the PA Process

This is the part that keeps care coordinators up at night. A patient needs their biologic, the PA is pending, and you've got a gap to manage.

Manufacturer patient assistance programs and bridge supply programs exist specifically for this scenario. Most specialty drug manufacturers have hubs — dedicated support teams that can provide bridge therapy while PA is pending. These programs aren't always easy to find, but your specialty pharmacy partners should know them cold. Build that relationship with your specialty pharmacy rep if you haven't already.

For patients on Medicare, the Extra Help/LIS program can affect what PA criteria apply, and some CMS policies limit how Medicare Part D plans can apply step therapy for certain drug classes. Know your rights here, especially for any oncology or immunosuppressive medications.

---

April 2026 doesn't have to be a crisis if you start now. Pull your specialty drug PA volume from the last six months, identify your top 10 drugs by submission frequency, and do a quick audit of current payer criteria for each one. Flag where requirements are changing and update your team before the new criteria hit. The practices that stay ahead of these changes protect their patients from therapy gaps — and save themselves dozens of hours in rework every month. That's worth the prep time.